Completed PHASE1 INTERVENTIONAL 4-arm NCT02259595

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects

Sponsor: Otologic Pharmaceutics, Inc.

Conditions Hearing Loss Noise-Induced Hearing Loss Sensorineural Hearing Loss

Interventions HPN-07 NAC Placebo

Updated 6 times since 2017 Last updated: Apr 29, 2015 Started: Oct 31, 2014 Primary completion: Jan 31, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hearing Loss and Noise-Induced Hearing Loss, this trial is completed. The trial is conducted by Otologic Pharmaceutics, Inc. and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otologic Pharmaceutics, Inc.

Data source: Otologic Pharmaceutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Raleigh, United States